nubeqa
bayer ag - darolutamide - stækkun Æxli, gelding-Þola - innkirtla meðferð - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
finasteride alvogen filmuhúðuð tafla 5 mg
alvogen ehf. - finasteridum inn - filmuhúðuð tafla - 5 mg
duta tamsaxiro hart hylki 0,5/0,4 mg
medical valley invest ab - dutasteridum inn; tamsulosinum hýdróklóríð - hart hylki - 0,5/0,4 mg
duodart hart hylki 0,5/0,4 mg
glaxosmithkline pharma a/s - dutasteridum inn; tamsulosinum hýdróklóríð - hart hylki - 0,5/0,4 mg
dutaprostam hart hylki 0,5/0,4 mg
zentiva k.s.* - dutasteridum inn; tamsulosinum hýdróklóríð - hart hylki - 0,5/0,4 mg
dutasteride/tamsulosin teva (dutasteride/tamsulosinehydrochloride teva) hart hylki 0,5 mg/0,4 mg
teva b.v.* - dutasteridum inn; tamsulosinum hýdróklóríð - hart hylki - 0,5 mg/0,4 mg
xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
erleada
janssen-cilag international nv - apalutamide - blöðruhálskirtli - innkirtla meðferð - erleada er ætlað:í fullorðnir menn í meðferð ekki sjúklingum gelding þola krabbamein í blöðruhálskirtli (nmcrpc) sem eru á mikil hætta á að fá sjúklingum sjúkdómur. í fullorðnir menn fyrir meðferð af sjúklingum hormón-viðkvæm krabbamein í blöðruhálskirtli (mhspc) ásamt andrógen skort meðferð (adt).
efmody
diurnal europe b.v. - hýdrókortisón - adrenal hyperplasia, congenital - barksterar til almennrar notkunar - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.
cinacalcet wh filmuhúðuð tafla 30 mg
williams & halls ehf. - cinacalcetum hýdróklóríð - filmuhúðuð tafla - 30 mg